Atorvastatin fails to slow atherosclerosis in pediatric SLE

10/27/2011 |

A study of 221 patients aged 10 to 21 years old with pediatric systemic lupus erythematosus found that taking atorvastatin for three years had no significant effect on subclinical atherosclerosis progression. Researchers failed to find any significant differences in progression of mean-mean common carotid intima-media thickening between those who took atorvastatin and those on placebo, but found reduced high-sensitivity C-reactive protein, low-density lipoprotein and total cholesterol levels in the statin group. The findings appear in the journal Arthritis & Rheumatism.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID